HK1023788A1 - Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof. - Google Patents

Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof.

Info

Publication number
HK1023788A1
HK1023788A1 HK00100567A HK00100567A HK1023788A1 HK 1023788 A1 HK1023788 A1 HK 1023788A1 HK 00100567 A HK00100567 A HK 00100567A HK 00100567 A HK00100567 A HK 00100567A HK 1023788 A1 HK1023788 A1 HK 1023788A1
Authority
HK
Hong Kong
Prior art keywords
pep
joined
enhancing peptide
immunoconjugates
fusion protein
Prior art date
Application number
HK00100567A
Other languages
English (en)
Inventor
Alan L Epstein
Leslie A Khawli
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of HK1023788A1 publication Critical patent/HK1023788A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/55IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK00100567A 1998-01-09 2000-01-28 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof. HK1023788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2219961A CA2219961C (en) 1998-01-09 1998-01-09 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
AU51821/98A AU5182198A (en) 1998-01-09 1998-01-12 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
EP98100603A EP0931836B1 (de) 1998-01-09 1998-01-15 Peptid aus humanem Interleukin-2 zur Steigerung der Vasopermeabilität und dessen Immunkonjugate

Publications (1)

Publication Number Publication Date
HK1023788A1 true HK1023788A1 (en) 2000-09-22

Family

ID=31720801

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00100567A HK1023788A1 (en) 1998-01-09 2000-01-28 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof.

Country Status (7)

Country Link
EP (1) EP0931836B1 (de)
AT (1) ATE263247T1 (de)
AU (1) AU5182198A (de)
CA (1) CA2219961C (de)
DE (1) DE69822779T2 (de)
ES (1) ES2218717T3 (de)
HK (1) HK1023788A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
IL91933A (en) * 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
JPH0720991B2 (ja) * 1989-02-08 1995-03-08 株式会社クラレ 新規なペプチドおよびその用途

Also Published As

Publication number Publication date
DE69822779T2 (de) 2005-03-10
CA2219961A1 (en) 1999-07-09
ES2218717T3 (es) 2004-11-16
EP0931836B1 (de) 2004-03-31
ATE263247T1 (de) 2004-04-15
CA2219961C (en) 2010-06-01
AU5182198A (en) 1999-07-29
EP0931836A1 (de) 1999-07-28
DE69822779D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
ES2134212T3 (es) Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
ATE373712T1 (de) Natürlicher menschlicher antikörper
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE69807679T2 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
TR200002885T2 (tr) İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
DE60238503D1 (de) Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
EP1354896A4 (de) Neuer monoklonaler antikörper
HK1023788A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof.
ES2228903T3 (es) Pegilacion de ligandos que mejora la actividad antitumoral y reduce la toxicidad de inmunoconjugados.
IL141647A0 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
MX2023005571A (es) Metodos de tratamiento de canceres que expresan axl con anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados.
RU2023123071A (ru) Способы предотвращения окисления метионина в иммуноконъюгатах

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100115